Report of 12 months efficacy and safety of iluvien (0.2 μg/d fluocinolone acetonide [FAC]) for chronic diabetic macular edema in Portugal

Session Details

Session Title: Free Paper Session 23: Vascular Diseases & Diabetic Retinopathy VI

Session Date/Time: Sunday 10/09/2017 | 08:00-09:30

Paper Time: 08:48

Venue: Room 120

First Author: : A.Meireles PORTUGAL

Co Author(s): :    C. Teixeira   J. Castro e Sousa   M. Falcao   J. Coelho   R. Goncalves   B. Pessoa              

Abstract Details

Purpose:

To report the 12-months functional and anatomical outcomes of chronic diabetic macular edema (DME) patients treated with ILUVIEN in real-clinical practice in four portuguese clinical centres.

Setting:

Angelina Meireles 1 Carla Teixeira 2, João Paulo Castro e Sousa 3, Manuel Falcão 4, João Coelho 1, Rita Gonçalves 2, Bernardete Pessoa1 1 CH Universitário do Porto, 2 UL de Matosinhos , 3 Centro Hospitalar de Leiria; 4 Centro Hospitalar de São João

Methods:

Retrospective data collection and analysis of consecutive 37 eyes of 30 patients received ILUVIEN implant for DME. Outcome measures included mean changes in best-corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study (ETDRS) letters, central foveal thickness (CFT) and intraocular pressure (IOP) at 1, 3, 6, 9 and 12 months.

Results:

The ratio of pseudophakic:phakic eyes was 29:8, respectively. Baseline mean BCVA was 38.1±2.8 (mean ± standard error [SE]) letters improved to 47.2±3.5 letters (P=0.001) at 12 months. BCVA was improved or maintained in 84.8% eyes, and 42.4% gained ≥15 letters, and 63.4% eyes gained ≥10 letters from baseline. The percentage of eyes achieved ≥70 ETDRS was 12% from baseline at 12 months. Mean CRT decreased by -220.2±32.1 μm from baseline to 330.9±32.5 μm at 12 months (P=0.001). At baseline 27.3% of patients were being treated with IOP-lowering medication. At last observation 54.5% eyes were being managed with IOP lowering medication.

Conclusions:

Real-life outcomes show that the funtional and the anatomical improvements achieved with ILUVIEN implant were maintained up to 12 months with minimal need of top-up therapy. IOP a know class effect of steroids was manageable with combination therapy. These results demonstrate that ILUVIEN is an effective long-term option in treating chronic DME.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy